Your browser is no longer supported. Please, upgrade your browser.
Curis, Inc.
Index- P/E- EPS (ttm)-0.82 Insider Own6.90% Shs Outstand54.55M Perf Week-7.04%
Market Cap912.75M Forward P/E- EPS next Y-0.41 Insider Trans0.00% Shs Float51.42M Perf Month41.24%
Income-31.00M PEG- EPS next Q-0.10 Inst Own25.20% Short Float3.32% Perf Quarter836.75%
Sales11.10M P/S82.23 EPS this Y1.50% Inst Trans-4.30% Short Ratio0.18 Perf Half Y743.08%
Book/sh-0.52 P/B- EPS next Y31.00% ROA-81.30% Target Price15.75 Perf Year564.24%
Cash/sh0.28 P/C38.68 EPS next 5Y- ROE93.10% 52W Range0.62 - 13.44 Perf YTD33.82%
Dividend- P/FCF- EPS past 5Y2.30% ROI82.20% 52W High-18.45% Beta3.18
Dividend %- Quick Ratio3.10 Sales past 5Y0.30% Gross Margin95.10% 52W Low1667.74% ATR1.03
Employees28 Current Ratio3.10 Sales Q/Q-6.90% Oper. Margin- RSI (14)64.75 Volatility9.37% 11.23%
OptionableYes Debt/Eq- EPS Q/Q43.50% Profit Margin- Rel Volume0.15 Prev Close11.09
ShortableYes LT Debt/Eq- EarningsNov 10 AMC Payout- Avg Volume9.28M Price10.96
Recom2.00 SMA2014.32% SMA5084.64% SMA200376.82% Volume1,412,782 Change-1.17%
Jul-29-20Initiated Laidlaw Buy $5
Jul-17-20Initiated Cantor Fitzgerald Overweight $4
Oct-24-17Initiated Guggenheim Buy $7
Mar-02-16Initiated Sun Trust Rbsn Humphrey Buy $3
Nov-09-15Reiterated ROTH Capital Buy $6 → $5
Aug-11-15Initiated FBR Capital Outperform $6
Jan-22-15Reiterated Oppenheimer Outperform $3 → $5
Jan-21-15Reiterated ROTH Capital Buy $10 → $6
May-09-14Reiterated Oppenheimer Outperform $4.50 → $3
Oct-02-13Initiated Robert W. Baird Outperform $7
Sep-30-13Initiated Chardan Capital Markets Buy $6
Nov-14-12Initiated Stifel Nicolaus Hold
Jan-31-12Reiterated Summer Street Research Buy $5 → $7
Jan-31-12Reiterated Brean Murray Buy $5 → $6
Dec-09-11Initiated Oppenheimer Outperform $6
Oct-06-11Initiated Summer Street Research Buy $5
Sep-22-11Initiated MLV Capital Buy $8.50
Mar-21-11Reiterated Brean Murray Buy $4 → $5
Feb-26-10Reiterated Roth Capital Buy $5 → $4.50
Jan-07-10Initiated Roth Capital Buy $5
Jan-14-21 08:00AM  
Jan-08-21 04:01PM  
Jan-05-21 08:00AM  
Dec-22-20 04:05PM  
Dec-14-20 08:00AM  
Dec-11-20 08:44AM  
Dec-10-20 09:52PM  
Dec-09-20 03:02PM  
Dec-08-20 04:13PM  
Dec-07-20 01:30PM  
Dec-02-20 08:40AM  
Nov-24-20 09:51AM  
Nov-10-20 04:54PM  
Nov-04-20 01:29PM  
Nov-02-20 04:01PM  
Oct-21-20 08:00AM  
Oct-14-20 05:01PM  
Sep-18-20 07:05AM  
Sep-10-20 04:01PM  
Aug-04-20 04:01PM  
Jul-28-20 08:00AM  
Jul-07-20 08:00AM  
Jun-21-20 10:09PM  
Jun-11-20 09:25AM  
Jun-10-20 08:00AM  
Jun-04-20 07:24PM  
Jun-03-20 09:33AM  
May-12-20 04:01PM  
May-05-20 08:00AM  
Apr-07-20 08:00AM  
Apr-03-20 04:01PM  
Mar-19-20 04:01PM  
Mar-12-20 08:00AM  
Feb-27-20 08:00AM  
Feb-06-20 08:30AM  
Jan-13-20 08:00AM  
Jan-08-20 04:31PM  
Jan-07-20 08:05AM  
Dec-23-19 06:24PM  
Dec-22-19 08:33AM  
Dec-06-19 07:26AM  
Nov-20-19 10:07PM  
Nov-06-19 09:05AM  
Nov-05-19 07:00AM  
Oct-31-19 04:16PM  
Oct-29-19 08:00AM  
Oct-04-19 04:05PM  
Sep-26-19 08:00AM  
Sep-23-19 12:07PM  
Sep-12-19 08:00AM  
Aug-06-19 04:01PM  
Jul-30-19 08:00AM  
Jul-25-19 03:49PM  
Jul-05-19 04:01PM  
Jun-12-19 07:00AM  
May-21-19 11:20AM  
May-14-19 04:29PM  
May-07-19 08:00AM  
May-06-19 08:00AM  
Apr-26-19 03:13PM  
Apr-10-19 08:00AM  
Apr-05-19 04:30PM  
Mar-27-19 10:16PM  
Mar-26-19 04:17PM  
Mar-25-19 12:05PM  
Mar-04-19 08:00AM  
Feb-04-19 07:00AM  
Jan-29-19 09:30AM  
Jan-24-19 07:00AM  
Jan-10-19 05:53PM  
Jan-08-19 12:58PM  
Jan-04-19 04:00PM  
Nov-30-18 07:45AM  
Nov-20-18 10:45AM  
Nov-07-18 04:05PM  
Nov-05-18 09:09AM  
Nov-01-18 10:41AM  
Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include CA-4948, an oral small molecule drug candidate, which is in Phase I clinical trial for the treatment of non-hodgkin lymphomas, and acute myeloid leukemia and myelodysplastic syndromes; CI-8993, a monoclonal antibody designed to antagonize the V-domain Ig suppressor of T cell activation; and Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with MYC-altered diffuse large B-cell lymphoma and solid tumors. The company's products in pipeline include CA-170, an oral small molecule drug candidate for treating patients with advanced solid tumors and lymphomas; and CA-327, a pre-investigational new drug stage oncology drug candidate. It has collaboration agreement with F. Hoffmann-La Roche Ltd. and Genentech Inc. for the development and commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway inhibitor for the treatment of advanced basal cell carcinoma; Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology; and DarwinHealth, Inc. to characterize biomarkers and tumor subtype alignments to identify therapeutic opportunities. The company was founded in 2000 and is headquartered in Lexington, Massachusetts.